Sunadaran ɗan adam yana inganta aikin tsoka na mice dystrophy na tsoka
Sunadaran ɗan adam yana inganta aikin tsoka na mice dystrophy na tsoka
Anonim

Wani sabon abu mai yuwuwar maganin da ya dogara akan furotin ɗan adam na halitta yana rage lalacewar tsoka sosai kuma yana haɓaka aiki a cikin ɓeraye waɗanda ke da maye gurbi iri ɗaya kamar maza waɗanda ke da nau'in dystrophy na muscular na yau da kullun, a cewar wata takarda da aka buga akan layi Dec. 27 a cikin Ci gaba na Kwalejin Kimiyya ta Kasa.

Duchenne Muscular Dystrophy shine maye gurbi mai saurin mutuwa a cikin kusan ɗaya daga cikin kowane maza 3, 500. Ba sa iya samar da furotin da ake kira dystrophin wanda ke ƙarfafa tsokoki. Da shekaru takwas, yaran sun fara samun matsala wajen tafiya. A lokacin samarinsu sukan kasance a cikin keken guragu, kuma a cikin shekaru 20 na aikin tsoka yana raguwa har suna mutuwa.

"Wannan duk an yi niyya ne don samun maganin da zai inganta yanayin marasa lafiya da ma'ana," in ji Justin Fallon, farfesa a fannin neuroscience a Jami'ar Brown kuma babban marubucin takardar. "Wannan wani muhimmin mataki ne akan wannan tafarki."

Wannan faɗuwar, kamfanin farawa Tivorsan Pharmaceuticals ya ba da izini daga Brown zuwa mahimmin furotin, biglycan, yana fatan kawo yuwuwar jiyya ta hanyar gwaji na asibiti.

Biglycan yana dawo da kasancewar furotin mai ƙarfafa tsoka da ake kira utrophin, wanda yawanci yakan zama a cikin ƙananan yara kawai. Utrophin har yanzu yana samuwa a cikin manya, amma a wurare kaɗan kuma ba inda zai iya taimakawa masu fama da dystrophy na muscular ba waɗanda ba za su iya samar da dystrophin ba, wanda ke kiyaye tsokoki masu girma.

Gwaje-gwaje masu ƙarfafawa

A cikin gwaje-gwajen da aka kwatanta a cikin takarda, ƙungiyar Fallon ta nuna cewa biglycan da aka ba da shi zuwa jini yana jawo utrophin zuwa sassan salula na ƙwayoyin tsoka. Kamar yadda utrophin ke yi lokacin da yake cikin 'yan tayi, jarirai da yara, sunadaran suna aiki don taimakawa sel su gina da kuma riƙe ƙarfinsu.

A cikin gwaji guda ɗaya, ƙungiyar Fallon ta sami raguwar kashi 50 cikin ɗari a cikin filaye masu “tsaka-tsaki” a cikin tsokar tsokar berayen biglycan da aka yi wa magani idan aka kwatanta da ɓerayen da ba a kula da su ba. Masanan halittu sun gane zaruruwa a matsayin masu nuna lahani da gyara nama na baya-bayan nan, don haka raguwa a cikinsu yana nuna cewa ƙwayar tsoka ba ta da lahani.

Har ila yau, ƙungiyar ta ƙaddamar da tsokoki na linzamin kwamfuta zuwa daidaitaccen gwajin damuwa inda ake shimfiɗa su a lokaci guda kuma suna yin kwangila. Gwajin a ƙarshe yana raunana koda lafiyayyen tsoka, amma a cikin gwaje-gwajen da masu bincike da mawallafa daga Jami'ar Pennsylvania suka yi, tsokoki na ɓangarorin ƙwayoyin cuta na muscular dystrophy da aka yi wa biglycan sun rasa ƙarfinsu da kashi 30 cikin 100 a hankali fiye da irin ɓerayen da ba a yi musu magani ba.

A cikin gwaje-gwajen da aka yi kwanan nan ta hanyar amfani da ingantaccen tsari na biglycan, Fallon ya ce, ƙungiyar ta ga adadin ya tashi zuwa kashi 50 cikin ɗari a wasu tsokoki, ma'ana cewa berayen da aka yi wa biglycan suna riƙe da ƙarin aikin su na dogon lokaci.

Fallon ya ce illar jiyya tare da biglycan ya kasance cikin watanni na gwaji. Yawancin gwaje-gwaje na asali don sakamako masu illa a lokacin wannan lokacin, kamar aikin koda da hanta, ba su nuna wani lahani daga maganin ba.

Tare da ingancin biglycan da ke bayyana a cikin ƙirar linzamin kwamfuta na Duchenne Muscular Dystrophy, Fallon yana ɗokin ganin ko zai iya inganta rayuwar dubban yara.

"Babban mataki na gaba shine gwaji a cikin mutane," in ji Fallon.

Shahararren taken